The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Antifungal Chemical Compounds Identified Using a C. elegans Pathogenicity Assay
Open accessAbstract
There is an urgent need for the development of new antifungal agents. A facile in vivo model that evaluates libraries of chemical compounds could solve some of the main obstacles in current antifungal discovery. We show that Candida albicans, as well as other Candida species, are ingested by Caenorhabditis elegans and establish a persistent lethal infection in the C. elegans intestinal track. Importantly, key components of Candida pathogenesis in mammals, such as filament formation, are also involved in nematode killing. We devised a Candida-mediated C. elegans assay that allows high-throughput in vivo screening of chemical libraries for antifungal activities, while synchronously screening against toxic compounds. The assay is performed in liquid media using standard 96-well plate technology and allows the study of C. albicans in non-planktonic form. A screen of 1,266 compounds with known pharmaceutical activities identified 15 (approximately 1.2%) that prolonged survival of C. albicans-infected nematodes and inhibited in vivo filamentation of C. albicans. Two compounds identified in the screen, caffeic acid phenethyl ester, a major active component of honeybee propolis, and the fluoroquinolone agent enoxacin exhibited antifungal activity in a murine model of candidiasis. The whole-animal C. elegans assay may help to study the molecular basis of C. albicans pathogenesis and identify antifungal compounds that most likely would not be identified by in vitro screens that target fungal growth. Compounds identified in the screen that affect the virulence of Candida in vivo can potentially be used as "probe compounds" and may have antifungal activity against other fungi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE GENETICS OF CAENORHABDITIS ELEGANS
Brenner, S. (1974) · Genetics · doi:10.1093/genetics/77.1.71 · Cited by 15,081
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Nonfilamentous C. albicans Mutants Are Avirulent
Lo, H.-J., Köhler, J. R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., & Fink, G. R. (1997) · Cell · doi:10.1016/s0092-8674(00)80358-x · Cited by 1,809
Candida biofilms and their role in infection
Douglas, L. J. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(02)00002-1 · Cited by 1,150
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055 · cited 1×
“The mortality rate for device-associated Candida infection can be even higher [4].”
BackgroundA Conserved p38 MAP Kinase Pathway in Caenorhabditis elegans Innate Immunity
Kim, D. H., Feinbaum, R., Alloing, G., Emerson, F. E., Garsin, D. A., Inoue, H., Tanaka-Hino, M., Hisamoto, N., Matsumoto, K., Tan, M.-W., et al. (2002) · Science · doi:10.1126/science.1073759 · Cited by 853
Self-citationKuhn, D. M., George, T., Chandra, J., Mukherjee, P. K., & Ghannoum, M. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1773-1780.2002 · Cited by 764
Adhesive and Mammalian Transglutaminase Substrate Properties of Candida albicans Hwp1
Staab, J. F., Bradway, S. D., Fidel, P. L., & Sundstrom, P. (1999) · Science · doi:10.1126/science.283.5407.1535 · Cited by 607
Candida albicans: A molecular revolution built on lessons from budding yeast
Berman, J., & Sudbery, P. E. (2002) · Nature Reviews Genetics · doi:10.1038/nrg948 · Cited by 578
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
A simple model host for identifying Gram-positive virulence factors
Garsin, D. A., Sifri, C. D., Mylonakis, E., Qin, X., Singh, K. V., Murray, B. E., Calderwood, S. B., & Ausubel, F. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191378698 · Cited by 568
Self-citationSteenbergen, J. N., Shuman, H. A., & Casadevall, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261418798 · Cited by 511
Critical Role of Bcr1-Dependent Adhesins in C. albicans Biofilm Formation In Vitro and In Vivo
Nobile, C. J., Andes, D. R., Nett, J. E., Smith, F. J., Yue, F., Phan, Q.-T., Edwards, J. E., Filler, S. G., & Mitchell, A. P. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020063 · Cited by 507 · cited 1×
“In vivo models for Candida biofilm are particularly cumbersome and expensive, as they usually entail the placement of vascular catheters in rabbits [39] or rats [40,41].”
BackgroundRegulation of Cell-Surface Genes and Biofilm Formation by the C. albicans Transcription Factor Bcr1p
Nobile, C. J., & Mitchell, A. P. (2005) · Current Biology · doi:10.1016/j.cub.2005.05.047 · Cited by 464
Andes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., & Pitula, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.6023-6031.2004 · Cited by 389
Kumamoto, C. A., & Vinces, M. D. (2005) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00616.x · Cited by 389
Sundstrom, P. (2002) · Cellular Microbiology · doi:10.1046/j.1462-5822.2002.00206.x · Cited by 336
Ramage, G., VandeWalle, K., López-Ribot, J. L., & Wickes, B. L. (2002) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(02)00853-4 · Cited by 334
Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis
Mylonakis, E., Ausubel, F. M., Perfect, J. R., Heitman, J., & Calderwood, S. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232568599 · Cited by 329
Self-citationThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“$1 billion per year and the average cost of candidemia for a single episode is about $40,000 (1997 United States dollar) [5,6].”
BackgroundCharacterization of a germ-line proliferation mutation in C. elegans
Beanan, M. J., & Strome, S. (1992) · Development · doi:10.1242/dev.116.3.755 · Cited by 308
Quantitative variation of biofilms among strains in natural populations of Candida albicans
Li, X., Yan, Z., & Xu, J. (2003) · Microbiology · doi:10.1099/mic.0.25932-0 · Cited by 304
Identification of novel antimicrobials using a live-animal infection model
Moy, T. I., Ball, A. R., Anklesaria, Z., Casadei, G., Lewis, K., & Ausubel, F. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604055103 · Cited by 294
Self-citationIn Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
ALTERNATIVE CANDIDA ALBICANS LIFESTYLES: Growth on Surfaces
Kumamoto, C. A., & Vinces, M. D. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.59.030804.121034 · Cited by 237
Kumamoto, C. A. (2002) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(02)00371-5 · Cited by 214
Watabe, M., Hishikawa, K., Takayanagi, A., Shimizu, N., & Nakaki, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306040200 · Cited by 213
Using the Nematode Caenorhabditis Elegans To Predict Mammalian Acute Lethality To Metallic Salts
Williams, P. L., & Dusenbery, D. B. (1988) · Toxicology and Industrial Health · doi:10.1177/074823378800400406 · Cited by 205
Origins of variation in the fungal cell surface
Verstrepen, K. J., Reynolds, T. B., & Fink, G. R. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro927 · Cited by 201
Immunomodulatory effect of caffeic acid phenethyl ester in Balb/c mice
Park, J. H., Lee, J. K., Kim, H. S., Chung, S. T., Eom, J. H., Kim, K. A., Chung, S. J., Paik, S. Y., & Oh, H. Y. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.01.013 · Cited by 189
Rabbit Model of Candida albicans Biofilm Infection: Liposomal Amphotericin B Antifungal Lock Therapy
Schinabeck, M. K., Long, L. A., Hossain, M. A., Chandra, J., Mukherjee, P. K., Mohamed, S., & Ghannoum, M. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1727-1732.2004 · Cited by 180
The nematode Caenorhabditis elegans as a model of organophosphate-induced mammalian neurotoxicity
Cole, R. D., Anderson, G. L., & Williams, P. L. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.09.013 · Cited by 168
Candida albicans Biofilm-Defective Mutants
Richard, M. L., Nobile, C. J., Bruno, V. M., & Mitchell, A. P. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.8.1493-1502.2005 · Cited by 162
Tackling both sides of the host–pathogen equation with Caenorhabditis elegans
Ewbank, J. J. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(01)01531-3 · Cited by 130
glh-1, a germ-line putative RNA helicase from Caenorhabditis, has four zinc fingers.
Roussell, D. L., & Bennett, K. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9300 · Cited by 125
Worms and Flies as Genetically Tractable Animal Models To Study Host-Pathogen Interactions
Mylonakis, E. E., & Aballay, A. (2005) · Infection and Immunity · doi:10.1128/iai.73.7.3833-3841.2005 · Cited by 115
Self-citationEstimating the Cost of Nosocomial Candidemia in the United States
Miller, L. G., Hajjeh, R. A., & Edwards, J. E. (2001) · Clinical Infectious Diseases · doi:10.1086/319613 · Cited by 109 · cited 1×
“$1 billion per year and the average cost of candidemia for a single episode is about $40,000 (1997 United States dollar) [5,6].”
BackgroundCandida albicans hyphal formation and virulence: is there a clearly defined role?
Kobayashi, S. D., & Cutler, J. E. (1998) · Trends in Microbiology · doi:10.1016/s0966-842x(98)01218-9 · Cited by 91
Deva, R., Shankaranarayanan, P., Ciccoli, R., & Nigam, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3047 · Cited by 89
Sılıcı, S., Koç, N., Ayangil, D., & Çankaya, S. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fpe05002x · Cited by 83
Burden of hospitalization of patients with Candida and Aspergillus infections in Australia
Slavin, M. A., Fastenau, J. M., Sukarom, I., Mavros, P., Crowley, S. J., & Gerth, W. C. (2003) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2003.05.001 · Cited by 69
Tang, R. J., Breger, J. A., Idnurm, A., Gerik, K. J., Lodge, J. K., Heitman, J., Calderwood, S. B., & Mylonakis, E. E. (2005) · Infection and Immunity · doi:10.1128/iai.73.12.8219-8225.2005 · Cited by 58
Self-citationStaab, J. F., Bahn, Y., & Sundstrom, P. (2003) · Microbiology · doi:10.1099/mic.0.26445-0 · Cited by 48
Switch of phenotype as an escape mechanism of the intruder
Odds, F. C. (1997) · Mycoses · doi:10.1111/j.1439-0507.1997.tb00556.x · Cited by 38
Effects of CAPE-like compounds on HIV replication in vitro and modulation of cytokines in vivo
Ho, C., Lin, S. C., Chou, M., Chen, F.-L., Hu, C., Chen, C., Lu, G., & Yang, C. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki244 · Cited by 30
In-vitro activity of antifungal agents in combination with four quinolones.
Ma, P., & Rogers, T. R. (1988) · PubMed · Cited by 23
Candida albicans Switches Mates
Gow, N. A. R. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00608-1 · Cited by 21
Cited by
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
Medically important bacterial-fungal interactions
Peleg, A. Y., Hogan, D. A., & Mylonakis, E. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2313 · Cited by 619
Self-citationAntifungal Therapy: New Advances in the Understanding and Treatment of Mycosis
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
A nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343
Self-citation
Metadata
- Authors
- Breger, J., Fuchs, B. B., Aperis, G., Moy, T. I., Ausubel, F. M., & Mylonakis, E.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-02-02
- Volume
- 3
- Issue
- 2
- Pages
- e18
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2070140841
- Cited by
- 332
- References
- 47
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.